Source: Bloomberg Sanofi, France’s biggest drugmaker, said it managed to retain key Genzyme Corp. (GENZ) executives following the acquisition of the U.S. biotechnology company. “The level of employee turnover has not changed significantly following the acquisition,” Sanofi Chief Executive Officer…

Source: Xconomy Amid all the comings and goings and CEOs changing jobs in the past week—see Rick Reidy of Progress Software (NASDAQ: PRGS), Mara Aspinall of On-Q-ity, and others—one person flew under the radar in Boston. He is Stéphane Bancel,…

Source: Reuters LONDON (Reuters) – French scientists have developed a novel hepatitis C vaccine that may offer the first effective way to prevent an infection that can cause chronic liver disease and cancer. There is currently no available vaccine for…

Source: Fiercebiotech Few Big Pharma companies have done as much as Sanofi to change the game plan in R&D. And if you drill down into the company’s second quarter report today, you’ll find a snapshot of just how successful the…

Source: Press Release The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical…

Source: GENOWAY Lyon, France – July 12, 2011 genOway (ALTERNEXT-NYSE EURONEXT: ALGEN ; ISIN : FR0004053510; http://www.genoway.com) and bluebird bio (CAMBRIDGE, Mass. USA, http://www.bluebirdbio.com), report today genOway acquisition of an exclusive worldwide license for the RMCE technology (developed at the…

Source: VIVALIS

Source: FIERCEPHARMA Sanofi is seeing its increased focus on biotech drugs go according to plan, with positive results today from a late-stage trial of a multiple sclerosis treatment, Lemtrada, which the French drugmaker picked up through its $20 billion-plus buyout…

PARIS & LA JOLLA, Calif.–(BUSINESS WIRE)–Regulatory News: – Significant scientific advances stemming from the 2008-2011 collaboration – The “Ipsen Life Sciences Program” at the Salk Institute is renewed for a period of 3 years Ipsen (Paris:IPN)(Euronext: IPN; ADR: IPSEY) and…